Federal IDR outcomes: Intraoperative neuromonitoring in Delaware
In 2025 Q1–Q4, the provider or facility offer prevailed in 90.5% of 1,166 determined Federal IDR dispute line items for intraoperative neuromonitoring in Delaware. The median prevailing offer was 13.76x the QPA (25th–75th percentile 8.38x–21.79x; n = 1,131). The median time to a decision was 27 business days (n = 1,166).
Determined line items
1,166
2025 Q1–Q4 · 0 split decisions excluded
Provider win rate
90.5%
n = 1,166 · 2025 Q1–Q4
Median payment vs QPA
13.76x
middle half 8.38x–21.79x · n = 1,131 · 2025 Q1–Q4
Median days to decision
27
business days, from dispute initiation · n = 1,166 · 2025 Q1–Q4
Dollar amounts are not shown for specialty groups: the CMS QPA and Offers file, the only source of dollar figures, has no specialty field. See methodology.
By period
| Period | Line items | Win % | Median ×QPA | 25th–75th | Ratio n | Median days |
|---|---|---|---|---|---|---|
| 2025 Q1–Q4 | 1,166 | 90.5% | 13.76x | 8.38x–21.79x | 1,131 | 27 |
| 2024 Q1–Q4 | 987 | 81.8% | 11.86x | 5.72x–17.00x | 927 | 67 |
| 2023 Q1–Q4 | 188 | 63.3% | 5.48x | 1.12x–14.86x | 170 | 57 |
| 2023 Q1–2025 Q4 | 2,341 | 84.6% | 12.78x | 6.64x–21.15x | 2,228 | not pooled |
Line items = determined dispute line items (n). Win rate excludes split decisions and includes default decisions. Ratio n = line items reporting a payment-to-QPA ratio. Days are business days as reported by CMS (2023–2024: from IDR entity assignment; 2025: from initiation) and are never pooled.
Most disputed CPT codes
| CPT code | Line items | Win % | Median ×QPA | Ratio n | Median days |
|---|---|---|---|---|---|
| 95938 Placement of skin electrodes and measurement of stimulated sites on arms and leg | 364 | 90.9% | 25.19x † | 356 | 27 |
| 95939 Placement of skin electrodes and measurement of central motor stimulation in arm | 356 | 89.6% | 12.78x | 347 | 27 |
| 95941 Continuous remote monitoring of nervous system during operation, each hour | 297 | 90.6% | 8.38x | 291 | 31 |
| 95870 Needle measurement of electrical activity in arm, leg, trunk or head muscles, li | 52 | 88.5% | 7.69x | 50 | 35.5 |
2025 Q1–Q4 · rows with n ≥ 30 determined line items · sorted by n.
Related: all specialties in Delaware · Intraoperative neuromonitoring in all states
FAQ
What is the Federal IDR provider win rate for intraoperative neuromonitoring in Delaware?
In 2025 Q1–Q4, the provider or facility offer was selected in 90.5% of 1,166 determined dispute line items for intraoperative neuromonitoring in Delaware. Split decisions are excluded from the denominator and default decisions are included. Withdrawn, settled and ineligible disputes are not in the CMS data.
How do Federal IDR payments compare with the QPA for intraoperative neuromonitoring in Delaware?
In 2025 Q1–Q4, the median prevailing offer was 13.76x the qualifying payment amount (QPA), with a 25th to 75th percentile range of 8.38x to 21.79x (n = 1,131 line items). This uses the CMS field Prevailing Party Offer as % of QPA, where 1.00x equals the QPA.
How long do Federal IDR decisions take for intraoperative neuromonitoring in Delaware?
In 2025 Q1–Q4, the median was 27 business days (n = 1,166 line items), using the CMS field Length of Time to Make Determination (from dispute initiation).